Trial Profile
A Phase II, Multi-center, Open-label, Dose-finding Study to Evaluate Safety, Efficacy and Tolerability of Subcutaneously (SC) Administered rAvPAL-PEG in Patients With PKU for 24 Weeks
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pegvaliase (Primary)
- Indications Phenylketonuria
- Focus Pharmacokinetics
- Sponsors BioMarin Pharmaceutical
- 18 Jul 2018 Results from (NCT00634660, NCT01560286, NCT00925054, NCT01212744, NCT00924703, NCT01819727 and NCT01889862) published in the BioDrugs
- 24 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 08 Apr 2015 Planned End Date changed from 1 Jul 2015 to 1 Aug 2015 as reported by ClinicalTrials.gov record.